Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Amit Sanyal, MD: A Clinician’s Perspective

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Mar

Today In Oncology

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Amit Sanyal, MD: A Clinician’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery

Breast Cancer Recurrence Remains Low Even After 10 Years With Radiotherapy Tailored to Patient’s Individual Risk

Breast Reconstruction Using Polyurethane-Coated Implants May Reduce the Risk of Capsular Contracture, Additional Surgery

AI As Collaborator in Cancer Research and in Clinical Care

Metabolic Subtypes of Nasopharyngeal Carcinoma and Response to Treatment